Literature DB >> 3923911

Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides.

J C Sadoff, D C Wright, S Futrovsky, H Sidberry, H Collins, B Kaufmann.   

Abstract

Mouse monoclonal antibodies that react with O-side chain specific, O-side chain cross-reactive, and core P. aeruginosa lipopolysaccharide determinants have been isolated. The monoclonals directed at O-side chain determinants are generally opsonophagocytic with human neutrophils and human complement. They also protect mice from intraperitoneal and intravenous challenge and protect in the burned rat model of infection.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3923911     DOI： 10.1159/000410478

Source DB:  PubMed          Journal:  Antibiot Chemother (1971)        ISSN： 0066-4758


  12 in total

1.  Variation and adaptation of Pseudomonas aeruginosa toxicity to HeLa cells and fibroblasts.

Authors:  H Müller; C Kettelhack; M Kettelhack; H G Sonntag; G Keilich; R Brossmer; J Richards; V Kinzel; E Bäuerlein; H Pech
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

2.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

3.  Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.

Authors:  B J Stoll; M Pollack; L S Young; N Koles; R Gascon; G B Pier
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

4.  Visualization of Pseudomonas aeruginosa O antigens by using a protein A-dextran-colloidal gold conjugate with both immunoglobulin G and immunoglobulin M monoclonal antibodies.

Authors:  J S Lam; M Y Lam; L A MacDonald; R E Hancock
Journal:  J Bacteriol       Date:  1987-08       Impact factor: 3.490

5.  Production of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa.

Authors:  J S Lam; L A MacDonald; M Y Lam
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

6.  Glycosylation of pilin and nonpilin protein constructs by Pseudomonas aeruginosa 1244.

Authors:  Mohammed Qutyan; Matthew Henkel; Joseph Horzempa; Michael Quinn; Peter Castric
Journal:  J Bacteriol       Date:  2010-09-10       Impact factor: 3.490

7.  Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.

Authors:  S M Opal; A S Cross; J C Sadoff; H H Collins; N M Kelly; G H Victor; J E Palardy; M W Bodmer
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

8.  Subdivision of O serotypes of Pseudomonas aeruginosa with monoclonal antibodies.

Authors:  T A Vale; M A Gaston; T L Pitt
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

9.  Characterization of lipopolysaccharide-deficient mutants of Pseudomonas aeruginosa derived from serotypes O3, O5, and O6.

Authors:  T Dasgupta; T R de Kievit; H Masoud; E Altman; J C Richards; I Sadovskaya; D P Speert; J S Lam
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

10.  Heterogeneity of lipopolysaccharides from Pseudomonas aeruginosa: analysis of lipopolysaccharide chain length.

Authors:  M Rivera; L E Bryan; R E Hancock; E J McGroarty
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.